Hsbc Holdings PLC Aerie Pharmaceuticals Inc Transaction History

Hsbc Holdings PLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 11, 2022	SELL	$4.95 - $9.16 $5,430 - $10,048	-1,097 Reduced 6.32%	16,248 $120,000
Q1 2022 May 16, 2022	BUY	$5.64 - $9.8 $97,825 - $169,981	17,345 New	17,345 $159,000
Q1 2021 May 14, 2021	SELL	$13.12 - $20.9 $293,979 - $468,306	-22,407 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$9.12 - $14.49 $55,841 - $88,722	6,123 Added 37.6%	22,407 $302,000
Q3 2020 Nov 12, 2020	SELL	$10.46 - $14.46 $18,179 - $25,131	-1,738 Reduced 9.64%	16,284 $193,000
Q2 2020 Aug 14, 2020	BUY	$12.0 - $16.13 $216,264 - $290,694	18,022 New	18,022 $266,000
Q4 2019 Feb 14, 2020	SELL	$17.72 - $25.1 $453,915 - $642,961	-25,616 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$18.41 - $28.0 $471,590 - $717,248	25,616 New	25,616 $492,000

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Hsbc Holdings PLC, based on Form 13F filings with the SEC.

Stay updated on Hsbc Holdings PLC with notifications on news.